Applying Target Trial Emulation in Vaccine Research
JAMA Network Open · 20.11.2026 · 9 (11) · e2643921
DOI: 10.1001/jamanetworkopen.2026.43921 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA Network Open, online erschienen am 20.11.2026. Verfasst von Hao Dai und 12 weiteren Autor:innen. Die Arbeit nennt 110 Literaturangaben.
Abstract (Originalsprache)
Importance Target trial emulation (TTE) has emerged as a rigorous framework for strengthening causal inference in observational research, following the design principles of randomized clinical trials using clinical data. While TTE is increasingly applied in vaccine effectiveness and safety evaluations, its implementation, reporting practices, and alignment with regulatory standards for real-world evidence remain poorly characterized.
Objective
To evaluate the methodological rigor, reporting completeness, and regulatory alignment of observational vaccine studies that emulate a target trial. Evidence Review PubMed, Embase, and Web of Science were searched for peer-reviewed studies published between January 2021 and August 2025 that used clinical data to assess vaccine effectiveness or safety. Eligible studies explicitly or implicitly emulated a target trial through comparative, causal inference–based designs. Two reviewers independently screened and extracted data on adherence to TTE core design components (ie, eligibility, treatment strategies, assignment procedures, follow-up, outcomes, causal contrasts, and analysis plans) and alignment with regulatory real-world evidence guidance.
Findings
Among 79 studies meeting inclusion criteria, 58 covered COVID-19, 19 covered influenza, and 12 covered other vaccine-preventable diseases, including herpes zoster, mpox, pneumococcal disease, human papillomavirus, and other diseases. Only 25 studies (31.6%) reported clearly documented protocols. Although most studies delineated eligibility criteria, exposures, and outcomes, validation of operational definitions was infrequent (eligibility: 4 studies [5.1%]; exposure: 4 studies [5.1%]; outcome: 14 studies [17.7%]). For bias assessment and mitigation, 61 studies (77.2%) explicitly defined time zero, a key step in reducing immortal time and selection biases, while 26 studies (32.9%) used negative control to assess residual bias and only 2 studies (2.5%) used quantitative bias analysis using E-values. Despite regulatory emphasis on data credibility, systematic data quality assessments appeared in only 5 studies (6.3%). Conclusions and Relevance In this study, methodological rigor and transparency varied widely, with documented protocols, validated operational definitions, and systematic data quality assessments all uncommon. To improve reproducibility and regulatory credibility, future research should prioritize adopting standardized TTE reporting frameworks, ensure clearly documented protocols, and incorporate data quality assessments.
Zitieren
APA
Dai, H., Chang, T., He, X., Eiden, A., Wang, W. V., Cassell, K., Huang, Y., Kao, Y., Wang, D., Li, F., Mott, K., Zheng, Y., & Bian, J. (2026). Applying Target Trial Emulation in Vaccine Research. JAMA Network Open, 9(11), e2643921. https://doi.org/10.1001/jamanetworkopen.2026.43921
Vancouver
Dai H, Chang T, He X, Eiden A, Wang WV, Cassell K, et al. Applying Target Trial Emulation in Vaccine Research. JAMA Network Open. 2026;9(11):e2643921. doi:10.1001/jamanetworkopen.2026.43921
BibTeX
@article{Dai2026,
author = {Dai, Hao and Chang, Tien-yu and He, Xing and Eiden, Amanda and Wang, Wei (Vivian) and Cassell, Kelsie and Huang, Yi-Ling and Kao, Yu-Han and Wang, Dong and Li, Fangyu and Mott, Katrina and Zheng, Yi and Bian, Jiang},
title = {Applying Target Trial Emulation in Vaccine Research},
journal = {JAMA Network Open},
year = {2026},
volume = {9},
number = {11},
pages = {e2643921},
doi = {10.1001/jamanetworkopen.2026.43921}
}
EUVIMED